Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells, discover novel targets, engineer and manufacture antibodies and antibody drug conjugates.
Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors. Stemcentrx has assembled a talented and motivated team committed to this mission. We are recruiting people with world-class expertise in their practice, versatility, high energy and an entrepreneurial spirit.
Our state-of-the-art laboratories and manufacturing facilities are located in South San Francisco, California. We have a driven, ambitious, focused, hard-working, apolitical, fun, and collaborative culture that is more typical of Silicon Valley startups than large pharmaceutical companies. Our employees are compensated with salary, benefits and stock options.
Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors. Stemcentrx has assembled a talented and motivated team committed to this mission. We are recruiting people with world-class expertise in their practice, versatility, high energy and an entrepreneurial spirit.
Our state-of-the-art laboratories and manufacturing facilities are located in South San Francisco, California. We have a driven, ambitious, focused, hard-working, apolitical, fun, and collaborative culture that is more typical of Silicon Valley startups than large pharmaceutical companies. Our employees are compensated with salary, benefits and stock options.
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Sequoia Ca... | sequoiacap... |
| - | Founders F... | foundersfu... |
Mentions in press and media 5
| Date | Title | Description |
| 30.04.2016 | M&A roundup - week ending 4/30/16 | Rovi bought TiVo for $1.1B; Comcast bought DreamWorks for $3.8B; AbbVie bought Stemcentrx for $5.8B Spotify acquired CrowdAlbum, a company that makes live music events into shared experience. No financial terms of the deal were disclosed. T... |
| 28.04.2016 | AbbVie acquiring cancer drug startup StemcenTrx for $5.8 billion | Drug research giant AbbVie announced a deal to buy cancer drug startup Stemcentrx in a $5.8 billion cash and stock deal this morning. The terms of the deal include $2 billion in cash and $3.8 billion in stock upfront, plus another $4 billio... |
| 11.04.2016 | Top 10 Most Valuable Healthcare Startups | It's no secret that healthcare startups are hot right now. There are a lot of innovative companies out there trying to make it easier for everyone to get the care they need. These companies do everything from improving doctor/patient commun... |
| 08.09.2015 | Peter Thiel-backed ‘unicorn’ biotech posits that stem cells are root cause of cancer | The MIT Technology Review writes of the company: If hardly anyone has heard of Stemcentrx until now it is because the company has been hiding in plain sight. It occupies three floors on San Francisco’s bay overlooking the back gates of the ... |
| - | Peter Thiel-backed ‘unicorn’ biotech posits that stem cells are root cause of cancer | Stem CentRx, a stealth Peter Thiel-backed “unicorn,” posits that stem cells could be the underlying cause of many cancers. The San Francisco biotech startup’s core technology is meant to eliminate these cancer stem cells – and it’s found it... |